Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 24, 2006
Reporting Period: Event date January 24, 2006
This filing reports a specific corporate event regarding intellectual property rather than a standard financial reporting period.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a Current Report (Form 8-K) focused on a specific event and does not contain financial statements or performance metrics.
Material Changes
Intellectual Property Update: On January 24, 2006, the United States Patent and Trademark Office (USPTO) issued a "Notice of Allowance" for patent application 10/832,432. This application is part of the "Tuschl II" patent series.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) regarding the patent allowance but does not include specific management commentary, future guidance, or risk factors within the text of the 8-K itself.
Unusual Items: None reported beyond the standard patent allowance notification.
Investor Verification Checklist
- Verify the scope and claims of the "Tuschl II" patent series (Application 10/832,432) to understand its impact on the company's intellectual property portfolio.
- Review the attached press release (Exhibit 99.1) for additional details on the patent's commercial significance.
- Confirm the status of the patent issuance process following the "Notice of Allowance."